Imaging Plaque Inflammation in Higher-Risk Patients: What Do We Know and What Are We Looking For?

被引:0
|
作者
Ishai A. [1 ]
Tawakol A. [1 ,2 ]
机构
[1] Cardiac MR PET CT Program, Department of Imaging, Massachusetts General Hospital and Harvard Medical School Boston, 165 Cambridge Street, Suite 400, Boston, 02114-2750, MA
[2] Cardiology Division, Massachusetts General Hospital and Harvard Medical School Boston, 165 Cambridge Street, Suite 400, Boston, 02114-2750, MA
关键词
Atherosclerosis; FDG-PET; Inflammation;
D O I
10.1007/s12170-015-0459-0
中图分类号
学科分类号
摘要
Atherosclerosis is a chronic inflammatory condition complicating cholesterol accumulation within the artery wall. Inflammation is believed to play an important role in the formation, progression, and ultimately the rupture of atherosclerotic plaques (the principle event leading to most myocardial infarctions and strokes). An enhanced understanding of the inflammatory process within the atheroma may therefore facilitate risk stratification and treatment strategies. Molecular imaging techniques such as PET/CT have the ability to quantify arterial inflammation and assess the high-risk features of atheromas thus may be useful for identifying patients who are at higher risk for an atherothrombotic event. In this review, we focus on the potential of FDG-PET/CT as a tool to measure arterial inflammation, enhance risk stratification, and to evaluate novel therapies directed against atherosclerotic disease. Additionally, this review will provide a discussion on current challenges as well as future directions. © 2015, Springer Science+Business Media New York.
引用
收藏
页码:1 / 8
页数:7
相关论文
共 50 条
  • [31] Diversity: What We Know, What We Need to Know, and What We Need to Do
    Dukes, Charles
    Lamar-Dukes, Pamela
    RESEARCH AND PRACTICE FOR PERSONS WITH SEVERE DISABILITIES, 2009, 34 (3-4) : 71 - 75
  • [32] What do we know, what do we need to know and how do we apply it?
    Lawrence, G.
    RADIOTHERAPY AND ONCOLOGY, 2007, 84 : S37 - S37
  • [33] BRCA1: What do we know? What do we think we know? What do we really need to know?
    Buller, RE
    GYNECOLOGIC ONCOLOGY, 2000, 76 (03) : 291 - 293
  • [34] Ardhanarisvara: What We Know and What We Do not
    Goldberg, Ellen
    RELIGION COMPASS, 2008, 2 (03): : 301 - 315
  • [35] MANAGEMENT OF PATIENTS WITH ACUTE ASTHMA - WHAT DO WE KNOW - WHAT DO WE NEED TO KNOW
    MCFADDEN, ER
    ANNALS OF ALLERGY, 1994, 72 (04): : 385 - 389
  • [36] Food OIT What do we know, what don't we know, and what do we need to know?
    Ciaccio, Christina E.
    Bauer, Maureen Egan
    Nowak-Wegrzyn, Anna
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (02) : 118 - 119
  • [37] Syphilis and blood donors: What we know, what we do not know, and what we need to know
    Orton, S
    TRANSFUSION MEDICINE REVIEWS, 2001, 15 (04) : 282 - 291
  • [38] We know what we refuse - Do we know what we wish to have?
    Ondrejkovic, P
    SOCIOLOGIA, 1998, 30 (05): : 551 - 554
  • [39] Protein particles: What we know and what we do not know
    Ripple, Dean C.
    Dimitrova, Mariana N.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (10) : 3568 - 3579
  • [40] Cold urticaria - What we know and what we do not know
    Maltseva, Natalya
    Borzova, Elena
    Fomina, Daria
    Bizjak, Mojca
    Terhorst-Molawi, Dorothea
    Kosnik, Mitja
    Kulthanan, Kanokvalai
    Meshkova, Raisa
    Thomsen, Simon Francis
    Maurer, Marcus
    ALLERGY, 2021, 76 (04) : 1077 - 1094